A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Arformoterol
Delamanid
Rilpivirine may increase the QTc-prolonging activities of Delamanid.
Arformoterol
Tenofovir
The excretion of Tenofovir can be decreased when combined with Rilpivirine.
Arformoterol
Fosamprenavir
The serum concentration of Rilpivirine can be increased when it is combined with Fosamprenavir.
Arformoterol
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Rilpivirine.
Arformoterol
Lumefantrine
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Lumefantrine.
Arformoterol
Zuclopenthixol
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Zuclopenthixol.
Arformoterol
Ribociclib
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Ribociclib.
Arformoterol
Terodiline
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Terodiline.
Arformoterol
Macimorelin
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Macimorelin.
Arformoterol
Ivabradine
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Ivabradine.
Arformoterol
Tetrabenazine
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Tetrabenazine.
Arformoterol
Temafloxacin
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Temafloxacin.
Arformoterol
Lithium cation
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Lithium cation.
Arformoterol
Gilteritinib
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Gilteritinib.
Arformoterol
Benidipine
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Benidipine.
Arformoterol
Nilvadipine
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Nilvadipine.
Arformoterol
Dexverapamil
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Dexverapamil.
Arformoterol
Penfluridol
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Penfluridol.
Arformoterol
Otilonium
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Otilonium.
Arformoterol
Eperisone
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Eperisone.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3